BPG is committed to discovery and dissemination of knowledge
Articles in Press
5/20/2025 8:17:30 AM | Browse: 7 | Download: 0
Publication Name World Journal of Psychiatry
Manuscript ID 105249
Country China
Category Psychiatry
Manuscript Type Clinical Trials Study
Article Title Efficacy of Pediococcus acidilactici CCFM6432 in alleviating anhedonia in major depressive disorder: A randomized controlled trial
Manuscript Source Unsolicited Manuscript
All Author List Du-Xing Li, Qi-Ming Hu, Chen-Chen Xu, Hong-Yu Yang, Ji-Kang Liu, Yi-Fan Sun, Gang Wang, Jun Wang and Zhen-He Zhou
Funding Agency and Grant Number
Funding Agency Grant Number
the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Committee BJ2023086
Wuxi Taihu Talent Project WXTTP 2021
Corresponding Author Jun Wang, Department of Psychiatry, The Affiliated Mental Health Center of Jiangnan University, 156 Qianrong Road, Binhu District, Wuxi 214151, Jiangsu Province, China. woodfish2@126.com
Key Words Anhedonia; Probiotics; Depression; Event-related potentials; Reward processing
Core Tip Anhedonia, a core symptom of major depressive disorder (MDD), often exhibits poor responsiveness to conventional antidepressants, substantially impairing long-term prognosis. In our randomized controlled trial, adjunctive administration of Pediococcus acidilactici CCFM6432 alongside standard antidepressants demonstrated marked improvements in anhedonia, particularly anticipatory deficits, among MDD patients. Efficacy was quantified through the Temporal Experience of Pleasure Scale and task-specific electroencephalography biomarkers during the Guessing-Door Task, revealing enhanced reward anticipation neural signatures. These findings highlight CCFM6432's clinical potential in addressing anhedonia, with mechanistic implications for gut microbiota-brain axis modulation.
Citation Li DX, Hu QM, Xu CC, Yang HY, Liu JK, Sun YF, Wang G, Wang J, Zhou ZH. Efficacy of Pediococcus acidilactici CCFM6432 in alleviating anhedonia in major depressive disorder: A randomized controlled trial. World J Psychiatry 2025; In press
Received
2025-01-16 03:00
Peer-Review Started
2025-01-16 03:01
To Make the First Decision
Return for Revision
2025-03-18 09:09
Revised
2025-03-28 09:12
Second Decision
2025-05-09 09:25
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief
2025-05-20 08:17
Articles in Press
2025-05-20 08:17
Publication Fee Transferred
2025-04-01 08:22
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 2220-3206 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com